These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17784997)

  • 1. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs.
    Bonasia P; Cook C; Cheng Y; Ong S
    Curr Med Res Opin; 2007 Oct; 23(10):2477-83. PubMed ID: 17784997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium.
    Bonasia PJ; McVicar WK; Bill W; Ong S
    Respir Care; 2008 Dec; 53(12):1716-22. PubMed ID: 19025708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Kamin W; Schwabe A; Krämer I
    J Cyst Fibros; 2006 Dec; 5(4):205-13. PubMed ID: 16678502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Oct; 54(10):1342-7. PubMed ID: 19796414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compatibility of budesonide inhalation suspension with four nebulizing solutions.
    McKenzie JE; Cruz-Rivera M
    Ann Pharmacother; 2004 Jun; 38(6):967-72. PubMed ID: 15084687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
    Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA
    COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arformoterol tartrate in the treatment of COPD.
    Cazzola M; Hanania NA; Matera MG
    Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical compatibility of nebulizable drug admixtures containing budesonide and colistimethate or hypertonic saline.
    Klemmer A; Krämer I; Kamin W
    Int J Pharm Compd; 2013; 17(3):254-61. PubMed ID: 24046941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
    Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
    Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma.
    Hinkle J; Hinson J; Kerwin E; Goodwin E; Sciarappa K; Curry L; Hanrahan JP
    Pediatr Pulmonol; 2011 Aug; 46(8):761-9. PubMed ID: 21584948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator.
    Bauer A; McGlynn P; Bovet LL; Mims PL; Curry LA; Hanrahan JP
    Respir Care; 2009 Nov; 54(11):1488-92. PubMed ID: 19863833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
    Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
    Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of arformoterol and formoterol in COPD.
    Hanania NA; Donohue JF; Nelson H; Sciarappa K; Goodwin E; Baumgartner RA; Hanrahan JP
    COPD; 2010 Feb; 7(1):17-31. PubMed ID: 20214460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol.
    Itazawa T; Adachi Y; Ito Y; Higuchi O; Mochizuki H; Shimojo N; Inoue T
    Allergol Int; 2013 Mar; 62(1):131-5. PubMed ID: 23348859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
    Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
    Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of domiciliary nebulizers in managing patients with severe COPD.
    Eiser N; Angus K; McHale S
    Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pharmazie; 2007 Oct; 62(10):760-6. PubMed ID: 18236781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.